tiprankstipranks
Mineralys Therapeutics initiated with an Outperform at Evercore ISI
The Fly

Mineralys Therapeutics initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of Mineralys Therapeutics (MLYS) with an Outperform rating. Following the takeout of CinCor by AstraZeneca (AZN), Mineralys has a competitor molecule for which it ran a single trial in both resistant hypertension and uncontrolled hypertension and "appears to have worked in both," the analyst tells investors. Ultimately, Evercore expects Mineralys to replicate the efficacy results in larger trials, the firm added.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on MLYS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles